{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"Galinpepimut-S (GPS) vaccinations are started 12-22 days following autologous stem cell transplantation (ASCT). GPS and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants whose disease has not progressed and who are clinically stable (no active infection with fevers and no cardiovascular/respiratory compromise) may receive up to 6 additional monthly vaccinations. The use of post-ASCT maintenance therapy is allowed starting 3 months after ASCT.\n\nGalinpepimut-S: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule\n\nGM-CSF: subcutaneous injection\n\nMontanide: adjuvant\n\nlenalidomide: optional post-ASCT therapy\n\nbortezomib: optional post-ASCT therapy","id":"BG000","title":"Galinpepimut-S + Montanide + GM-CSF"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"72","value":"61.3"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"IgG"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"IgA"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Light chain"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Type of myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"3","value":"2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior therapies","unitOfMeasure":"number of therapies"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Lenalidomide alone or in combination"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Other (bortezomib)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Post ASCT therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"2"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior ASCT","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"High risk"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Average risk"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Cytogenetics at diagnosis","unitOfMeasure":"Participants"}],"populationDescription":"Analysis set"}